Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

By sjmartinez • October 17, 2022

Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Oct 13:S1470-2045(22)00603-9. doi: 10.1016/S1470-2045(22)00603-9. Epub ahead of print. PMID: 36244398.

Tags: Digestive Diseases, Hematology/Oncology, Publications

High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers

Ennin E, Mallepally N, Ali M, Shojaie L, Dewberry S, Trieu M, Torres ETR, Zhou K, Kahn J, Dodge JL, Dara L. High Grade Hepatotoxicity[...]

COVID-19 Pandemic-Related Disruptions in Routine Cirrhosis Care and Associated Clinical Outcomes among San Francisco Bay Area Veterans

Rubin JB, Loeb R, Monto A, Wong RJ, Cheung R, Batki SL, Ostacher MJ, Shen H, Hoggatt KJ, Satre DD, Khalili M. COVID-19 Pandemic-Related Disruptions[...]

Diesel exhaust induces gut microbiome dysbiosis and reduced fecal acetate: Role of acetate supplementation

Gupta R, Chang C, Vergnes L, Sulaiman D, Yin F, Stewart JA, Mehrabian M, Kaufman JD, Jacobs JP, Lusis AJ, Reue K, Rosenfeld ME, Araujo[...]